FDMT – 4d molecular therapeutics, inc. (US:NASDAQ)
Stock Stats
News
4DMT to Participate in Upcoming Investor Conferences
4DMT Announces New Employment Inducement Grants
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) [Yahoo! Finance]
4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.
Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: Novo Holdings A/S
Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: BIOTECHNOLOGY VALUE FUND L P
Form SCHEDULE 13G 4D Molecular Therapeutic Filed by: JANUS HENDERSON GROUP PLC
Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: GOLDMAN SACHS GROUP INC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.